FDA Approves First Plasmid DNA-based Immunotherapy for Adult RRP
The U.S. Food and Drug Administration has granted accelerated approval for Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for the treatment of adults with recurrent respiratory papillomatosis, a rare condition caused by human papillomavirus.
Voceryq is a recombinant plasmid DNA-based immunotherapy delivered via intramuscular injection using an electroporation device. Clinical trial data demonstrated that the treatment helps reduce the frequency of surgical procedures required to remove airway growths in adult patients.
Common adverse reactions associated with the treatment include injection site reactions, headache, fatigue, hypertension, nausea, and dizziness, alongside procedure-related effects such as temporary bleeding, brief muscle contractions, and pain.
Key points
- Voceryq is the first plasmid DNA-based immunotherapy approved in the U.S. for adult recurrent respiratory papillomatosis.
- Approval was granted under the accelerated pathway based on a reduction in surgical procedure frequency.
- The therapy is administered via intramuscular injection using the CELLECTRA 5PSP Device to facilitate electroporation.
- Common side effects include injection site reactions, headache, fatigue, hypertension, nausea, and dizziness.
What it means for you
This approval introduces a novel immunotherapeutic option targeting the root cause of recurrent respiratory papillomatosis in adults. Clinicians and pharmacists in Pakistan should check with the Drug Regulatory Authority of Pakistan regarding the local availability and registration status of this product.
FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis
Summarised automatically from the official announcement. For educational purposes only — check the original source before making clinical decisions.